Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Ownership  |  Insiders

Stock Quote Today & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with... see more

Current News (NYSEAM:ATNM)

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Newsfile 1 day ago

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

PR Newswire November 4, 2025

Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

PR Newswire November 3, 2025

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PR Newswire October 27, 2025

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 24, 2025

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PR Newswire October 13, 2025

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 13, 2025

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

PR Newswire July 31, 2025

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

PR Newswire June 23, 2025
View More News ››

Opinion & Analysis (NYSEAM:ATNM)

2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

The Life Sciences Report July 14, 2017

2017 Small-Cap biotech watchlist update: holding steady in a volatile market

The Life Sciences Report April 21, 2017

2017 Small-Cap Biotech Watchlist: takeaways for investors

The Life Sciences Report January 19, 2017

19 companies selected for the 2017 Small-Cap Biotech Watchlist

The Life Sciences Report January 5, 2017

Radioimmunotherapy 2.0:Actinium sets eyes on bone marrow transplant and AML with later stage programs

The Life Sciences Report August 17, 2016
View More Opinion ››

Bullboard Posts (NYSEAM:ATNM)

Buy buddy buy because it's taking off this morning.

Otherwise you guys will be missing out on this stock today
coolfooldumbguy - March 26, 2025

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
EllaMae - April 13, 2023

And good supporting article!

https://trendingmarketnews.com/biotechs-next-generational-breakout/
BryceCanada - November 2, 2022

Excellent YT analysis on ATNM!

https://youtu.be/EBO7c8N5bSI
BryceCanada - November 2, 2022

TIME TO TURN NORTH

BULLALERTS is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I dont...
wabomebuypo16 - November 2, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

 
EllaMae - July 15, 2022
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Canada-based an oil and natural gas company. The Company is engaged in the acquisition ...
View More »